Search

Your search keyword '"John Eikelboom"' showing total 101 results

Search Constraints

Start Over You searched for: Author "John Eikelboom" Remove constraint Author: "John Eikelboom"
101 results on '"John Eikelboom"'

Search Results

1. Optimizing warfarin dosing for patients with atrial fibrillation using machine learning

2. Could vaccinating adults against malaria materially reduce adult mortality in high-transmission areas?

3. Anticoagulation for mechanical aortic valves: An international survey of current practice patterns and perceptions

4. Corrigendum: Bleeding Risk Prediction in Patients Treated with Antithrombotic Drugs According to the Anatomic Site of Bleeding, Indication for Treatment, and Time Since Treatment Initiation

5. Bleeding Risk Prediction in Patients Treated with Antithrombotic Drugs According to the Anatomic Site of Bleeding, Indication for Treatment, and Time Since Treatment Initiation

6. Time to establish an international vaccine candidate pool for potential highly infectious respiratory disease: a community’s view

8. Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE – COALITION VIII randomised clinical trialResearch in context

9. The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges

10. Venous and arterial thrombosis in COVID-19: An updated narrative review

11. FUNCTIONAL OUTCOMES OF INDIVIDUALS WITH CARDIOVASCULAR DISEASE AFTER GASTROINTESTINAL CANCER

12. Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery

13. Validating fatty acid binding protein 3 as a diagnostic and prognostic biomarker for peripheral arterial disease: A three-year prospective follow-up studyResearch in context

14. Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF

15. Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease

16. Urinary fatty acid binding protein 3 (uFABP3) is a potential biomarker for peripheral arterial disease

17. Fatty acid binding protein 3 is associated with peripheral arterial disease

18. Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and kneE Replacement (PEPPER): the PEPPER trial protocol

19. Effect of a Perioperative Hypotension-Avoidance Strategy Versus a Hypertension-Avoidance Strategy on the Risk of Acute Kidney Injury: A Clinical Research Protocol for a Substudy of the POISE-3 Randomized Clinical Trial

20. Ross for Valve replacement In AduLts (REVIVAL) pilot trial: rationale and design of a randomised controlled trial

21. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome

22. Elevated plasma levels of NT-proBNP in ambulatory patients with peripheral arterial disease.

23. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

24. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.

25. Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants.

26. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

29. A hybrid automated event adjudication system for clinical trials

31. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

32. Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week

34. Rivaroxaban to Prevent Major Clinical Outcomes in Non-Hospitalised Patients with COVID-19: The Care – Coalition VIII Randomised Clinical Trial

36. Validating fatty acid binding protein 3 as a diagnostic and prognostic biomarker for peripheral arterial disease: A three-year prospective follow-up study

37. The cost-effectiveness of Rivaroxaban with or without aspirin in the COMPASS trial

38. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials

39. Efficacy and Safety of Intensified Versus Standard Prophylactic Anticoagulation Therapy in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis

40. The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges

41. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

42. Efficacy and safety of intensified versus standard prophylactic anticoagulation therapy in patients with Covid-19: a systematic review and meta-analysis

43. Tranexamic Acid in Patients Undergoing Noncardiac Surgery

44. Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances

45. Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves

46. Illustrated State‐of‐the‐Art Capsules of the ISTH 2019 Congress in Melbourne, Australia

47. Pulmonary embolism: update on diagnosis and management

48. Deep vein thrombosis: update on diagnosis and management

49. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease

50. The effect of low-dose colchicine on cause-specific mortality in the LoDoCo2 trial

Catalog

Books, media, physical & digital resources